Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

1.020 -0.010 (-0.97%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,411
Open 1.030
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.030
Today's Range 0.9690 - 1.030
52wk Range 0.8840 - 2.670
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Awakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research
Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions. 
Via Benzinga
Wake-Up Call: This Biotech Company Is Using Psychedelics To Treat Addiction
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga

Performance

YTD
-50.84%
-50.84%
1 Month
-6.93%
-6.93%
3 Month
-29.78%
-29.78%
6 Month
-56.85%
-56.85%
1 Year
-30.58%
-30.58%

More News

Read More
Core One Labs Begins Trading On OTCQB
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
Via Benzinga
Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
Via Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
Via Benzinga
Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Via Benzinga
Psychedelic And Cannabis Drug Stocks Continue Advance
Via Talk Markets
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
Via Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
Via Talk Markets
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
Via Talk Markets
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
Via Benzinga
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
Via Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
Via Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
Via Talk Markets
AWKNF: A Psychedelic's Stock Exhibiting Recent Price Appreciation
Via Talk Markets
Psychedelic Drug Stocks Continued To Decline Last Week
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.